TIDMBVX
RNS Number : 8691L
BiVictriX Therapeutics PLC
06 January 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED
UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014
WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL)
ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A
REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or the "Company" or the "Group")
Board Change
Dr. Michael Kauffman, M.D., Ph.D. appointed as Non-Executive
Chairman
Iain Ross to remain a Board member
Alderley Park, 6 January 2023 - BiVictriX Therapeutics plc (AIM:
BVX), an emerging biotechnology company applying a novel approach
to develop next generation cancer therapies using insights derived
from frontline clinical experience, announces that Dr. Michael
Kauffman, M.D., Ph.D. has been appointed as Non-Executive Chairman.
Dr Kauffman takes over from Iain Ross, who will continue as a
Non-Executive Director on the BiVictriX Board, but steps down as
Chairman due to other work commitments.
Prior to becoming Non-Executive Chairman, Dr. Kauffman was
appointed as Non-Executive Director of BiVictriX in January 2022.
He is a highly experienced cancer drug developer, having been
instrumental in the approval of several oncology therapeutics over
twenty years of working across preclinical research, clinical
development, regulatory strategy and commercialisation. As
Non-Executive Chairman, he will draw upon his previous experience
as Co-Founder and Chief Executive Officer of oncology company
Karyopharm Therapeutics Inc., which he guided from a discovery
stage biotechnology company to a commercial stage organisation,
with global approvals of XPOVIO(R). He also led the Kyprolis(R)
development programme at Proteolix and then Onyx Pharmaceuticals,
the Velcade(R) development programme at Millennium Pharmaceuticals,
and has held a number of senior positions at Millennium Predictive
Medicine and Biogen. Dr Kauffman currently holds other
Non-Executive Board positions at Verastem Oncology, Adicet Bio and
Kezar Life Sciences.
Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics
plc, commented: "With the recent identification of our lead
candidate, the transition of Michael Kauffman to Non-Executive
Chairman of the Board comes at a pivotal time in BiVictriX's
development. I am delighted to welcome Michael to his new role; no
doubt his wealth of expertise across oncology drug development will
continue to prove invaluable during the next stage of our
progression. I would like to also express gratitude on behalf of
the whole Company to Iain for his excellent support, taking us
through from IPO to candidate identification and look forward to
continuing to work alongside him as a valued member of our
Board."
Dr. Michael Kauffman , Non-Executive Chairman of BiVictriX ,
added: "Having been a member of BiVictriX's Board over the past
year, I have witnessed the Company's remarkable progress and am
excited to step up to Chairman at this stage of the Company's
development. The Bi-Cygni(R) platform is designed to optimise the
potential of ADCs by reducing off target-binding associated with
toxicities and increasing tumor-selective killing. I am looking
forward to BiVictriX progressing BVX001 into the clinic, where we
hope to be differentiated by our delivery of key outcomes in
cancer-selective therapies for the support of patients who
currently have limited options."
Iain Ross, Non-Executive Director at BiVictriX, commented: "It
has been a privilege to have chaired the BiVictriX Board over the
past couple of years and to have seen it grow into such a strong
position. I am now, as a result of additional responsibilities at
ReNeuron Group plc, handing over the reins to Michael, who is well
experienced to support the Company as Chairman as it enters its
next stage of pipeline development. I look forward to remaining
actively involved in BiVictriX as a Non-Executive Director."
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Michael Kauffman, Non-Executive Email: info@bivictrix.com
Chairman
SP Angel Corporate Finance LLP Tel: +44 (0) 20 3470 0470
(NOMAD and Broker)
David Hignell, Kasia Brzozowska
(Corporate Finance)
Vadim Alexandre, Rob Rees (Sales
and Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886 2500
Broker)
Rupert Dearden, Freddy Crossley,
Emma Earl
Consilium Strategic Communications
Mary-Jane Elliott, Namrata Taak, Tel: +44 (0) 20 3709 5700
Genevieve Wilson, Alex Gunter Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a new
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst significantly reducing
treatment-related harmful side effects.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) therapeutics which are designed
to selectively target cancer-specific antigen pairs, or "twin
antigens fingerprints", on tumour cells, which are largely absent
from healthy cells. Whereas this concept has been validated in a
clinical diagnostic setting to support the diagnosis and monitoring
of haematological cancers, it has not yet been widely used in a
therapeutic setting, where it offers the opportunity to be a
game-changing approach to cancer care.
BiVictriX has identified a diverse panel of novel
cancer-specific "twin antigens fingerprints" across a broad range
of cancer indications. The Company is using these novel twin
antigens to develop more effective and safer therapeutics to target
cancers that are expected to constitute orphan indications and
areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASSLESIEDSEIF
(END) Dow Jones Newswires
January 06, 2023 02:00 ET (07:00 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Apr 2024 to May 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From May 2023 to May 2024